First known case of a potentially deadly heart rhythm disturbance induced by chloroquine therapy for COVID-19 reported

Clinicians should carefully monitor patients treated with chloroquine therapy, particularly elderly women and others at higher risk for heart rhythm abnormalities, investigators caution in the journal Heart Rhythm
19-Jun-2020 12:35 PM EDT, by Elsevier

Newswise — Philadelphia, June 18, 2020 - A patient who met many of the published safety guidelines for chloroquine therapy against COVID-19 was observed to have a very abnormal ECG pattern after treatment began, leading to multiple episodes of torsade de pointes (TdP), a life-threatening arrhythmia in which the lower chambers of the heart beat out of sync with the upper chambers. Her condition was resolved after chloroquine was discontinued, investigators report in Heart Rhythm, the official journal of the Heart Rhythm Society, the Cardiac Electrophysiology Society, and the Pediatric & Congenital Electrophysiology Society, published by Elsevier.

Chloroquine and hydroxychloroquine are commonly used to treat malaria and some rheumatic diseases. Their use as a treatment for COVID-19 has been widely debated in medical journals and the popular press. The authors of this case report present the first description of TdP due to chloroquine treatment in a patient with COVID-19.

Lead investigator Yishay Szekely, MD, Department of Cardiology, Sourasky Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, observes, "On the one hand, these drugs are known to cause prolongation of a specific ECG interval called QT interval. On the other hand, there is no evidence of sudden, unexplained death when they are used to treat malaria. And by the same token, neither the American nor the European rheumatology societies recommend electrocardiographic (ECG) surveillance for patients who receive long-term treatment with hydroxychloroquine."

The patient, an 84 year-old women with a history of breast cancer and controlled hypertension was admitted to the hospital with COVID-19. Her medications included letrozole, prescribed for breast cancer, and memantine, prescribed for Alzheimer's disease. An ECG found her corrected QT (QTc) interval was 462 milliseconds, borderline high but still below the 500-millisecond limit suggested by safety guidelines for chloroquine treatment. Her condition worsened and chloroquine therapy was introduced. After five days of treatment, there was no change to her clinical status, however, a follow-up ECG showed signs of an extremely elongated QTc interval of 627 milliseconds. Chloroquine was discontinued, as were other drugs known or suspected of causing QT-prolongation, including memantine and letrozole.

The patient was placed on a continuous ECG monitor and given potassium supplements to prevent arrhythmias. Six hours later episodes of TdP were noted on her ECG. She received treatment that led to an immediate resolution of the ventricular arrhythmias, and her QT interval gradually normalized. She was released after two weeks.

Dr. Szekely notes that the memantine the patient was taking likely contributed to the proarrhythmic effects of chloroquine. However, her QTc interval spiked only after chloroquine was introduced. "This clearly points to chloroquine as the culprit drug of her TdP." The breast cancer medication letrozole is actually considered safer from a QT interval point of view than other medications used to treat breast cancer.

"Chloroquine therapy is not free of risk in patients with COVID-19, particularly in those with high risk features for QT prolongation and TdP," says Dr. Szekely. "Given its questionable efficacy in the treatment of COVID-19 and risk of QT interval prolongation and torsade de pointes, chloroquine treatment must be considered thoroughly and reviewed on a regular basis."

###

SEE ORIGINAL STUDY



Filters close

Showing results

110 of 6084
Newswise: Public
Released: 28-Jul-2021 2:45 PM EDT
Highly Potent, Stable Nanobodies Stop SARS-CoV-2
Max Planck Society (Max-Planck-Gesellschaft)

Göttingen researchers have developed mini-antibodies that efficiently block the coronavirus SARS-CoV-2 and its dangerous new variants.

Newswise: Public
Released: 28-Jul-2021 2:20 PM EDT
Psychological Consequences of COVID-19 in Health Care
University of Bonn

Physicians, nursing staff, medical technical assistants, and pastoral workers in hospitals: they have all been placed under severe strain by the Covid-19 pandemic.

Newswise: Public
Released: 28-Jul-2021 2:10 PM EDT
Why Lockdown in Africa Does Not Work as a First COVID-19 Pandemic Response
University of Johannesburg

In an African pandemic it is more productive to consider lockdowns, after using other non-medical measures first, Especially in countries with high levels of poverty and corruption, says Prof Nicholas Ngepah, a Professor of Economics at the University of Johannesburg in South Africa.

Newswise:Video Embedded how-to-talk-with-people-who-are-not-vaccinated-against-covid-19
VIDEO
Released: 28-Jul-2021 1:40 PM EDT
How to Talk With People Who Are Not Vaccinated Against COVID-19
Cedars-Sinai

Even though she has asthma, putting her at higher risk for severe complications from COVID-19, Angela Reeves-Flores, 33, waited until a week ago to get vaccinated.

Newswise: Indian Women’s Nutrition Suffered During COVID-19 Lockdown
Released: 28-Jul-2021 12:50 PM EDT
Indian Women’s Nutrition Suffered During COVID-19 Lockdown
Cornell University

A new study from Cornell University finds the nationwide lockdown India imposed last year in response to COVID-19 caused disruptions that negatively impacted women’s nutrition.

Released: 28-Jul-2021 12:00 PM EDT
MD Anderson Research Highlights for July 28, 2021
University of Texas M. D. Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a newly discovered protein that controls B cell survival, understanding epigenetic changes in malignant peripheral nerve sheath tumors (MPNSTs) and melanoma, identifying a protein that protect genome stability, developing novel cell therapies for COVID-19, a new option for treating neuropathic pain, exosome delivery of CRISPR/Cas9 to pancreatic cancer, discovering how cancer cells tolerate aneuploidy and the role of health disparities in long-term survival of adolescent and young adult patients with Hodgkin lymphoma.

Released: 28-Jul-2021 11:30 AM EDT
Study Reveals Characteristics of SARS-CoV-2 Spike Protein
University of Kentucky

A new University of Kentucky College of Medicine study published in the Journal of Biological Chemistry provides foundational information about SARS-CoV-2’s spike protein.

access_time Embargo lifts in 2 days
Embargo will expire: 4-Aug-2021 9:00 AM EDT Released to reporters: 28-Jul-2021 11:15 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 4-Aug-2021 9:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: UIC Awarded $6 Million to Develop Potential COVID-19 Treatment
Released: 28-Jul-2021 10:15 AM EDT
UIC Awarded $6 Million to Develop Potential COVID-19 Treatment
University of Illinois Chicago

Researchers at the University of Illinois Chicago are developing a potential treatment for COVID-19, thanks to a $6 million technology and therapeutic development award from the U.S. Department of Defense supporting pre-clinical animal studies.

Newswise: Don’t Let the Raging Virus Put Life in Jeopardy. Chula Recommends How to Build an Immunity for Your Heart Against Stress and Depression
Released: 28-Jul-2021 8:55 AM EDT
Don’t Let the Raging Virus Put Life in Jeopardy. Chula Recommends How to Build an Immunity for Your Heart Against Stress and Depression
Chulalongkorn University

Cumulative stress, denial, and chronic depression are the byproducts of the COVID-19 pandemic. The Center for Psychological Wellness, Chulalongkorn University recommends ways to cope by harnessing positive energy from our heart.


Showing results

110 of 6084

close
23.70811